VEGFA and Alzheimer disease: Importantly, bevacizumab treatment restored the levels of sVEGFR1 and full-length VEGFR2 proteins in 5×FAD mice to a level similar to that in wild-type mice, suggesting that the loss of the balance and physiological strength of VEGF signaling in the brain parenchyma of AD patients and mouse models may be critical for the development of BBB damage and cerebrovascular dysfunction.